Alzheimer's Biomarker Stratification in Cognitive Cohorts

Patient data from the Paris cohort and the BIODEGMAR cohort was examined using two stratification criteria: (i) according to clinical syndrome (cognitively unimpaired [CU], MCI, or dementia) and CSF amyloid status (Aβ−/Aβ+, as defined by Lumipulse CSF Aβ_1-42/40, Supplementary Table 3), resulting in six groups: CU Aβ−, CU Aβ+, MCI Aβ−, MCI Aβ+, dementia Aβ− and dementia Aβ+ (clinical diagnosis included in each group are available in Supplementary Tables 1 and 2); (ii) based on the Aβ (A) and tau (T) status defined using CSF Aβ_1–42/40 and p-tau181, respectively (Lumipulse®) into A−T−, A+T− and A+T+ (the A−T+ group considered suspected non-AD pathology [SNAP] was not included in the statistical analysis, but is depicted in the boxplots). The clinical diagnoses included in each group are available in Supplementary Tables 5 and 6). Additionally, CSF p-tau235 levels across clinical diagnostic groups for both cohorts are available in Supplementary Figure 1.